Logo

Horizon Reports the Completion of Patient Enrollment of Tepezza (teprotumumab-trbw) in P-IV Trial for Thyroid Eye Disease

Share this
Horizon Reports the Completion of Patient Enrollment of Tepezza (teprotumumab-trbw) in P-IV Trial for Thyroid Eye Disease

Horizon Reports the Completion of Patient Enrollment of Tepezza (teprotumumab-trbw) in P-IV Trial for Thyroid Eye Disease

Shots:

  • The company has completed the patient enrollment of the P-IV trial evaluating Tepezza vs PBO in a ratio (2:1) in 57 patients with TED associated with a low CAS. After the treatment is complete, proptosis nonresponders may elect to enter an OLE phase during which they will receive 8 Tepezza infusions
  • The primary efficacy of EPs is the change from baseline @24wk. in proptosis & the trial will also evaluate proptosis responder rate, diplopia responder rate, change in orbital pain, change in muscle volume & GO-QoL questionnaire appearance, and visual functioning subscales. The results are expected in Q2’23
  • Additionally, the results showed an improvement in debilitating symptoms of TED in patients with inflammatory disease

Ref: Horizon   | Image: Horizon 

Click here to­ read the full press release 

Neha

Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions